Benjamin Solomon, MD
Hematology & Oncology · Salt Lake City, UTNPI 1518209485
Payments from drug & device makers
Across 148 payments — averaging $52.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$4K
- Johnson & Johnson$1K
- Geron Corporation$780
- Novartis$305
- Pfizer$291
- AstraZeneca$246
- plus $2K from 25 others
What the payments were for
- Consulting fees$4,76061%
- Food & beverage$2,90837%
- Education$1572%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 24 | $3,570 |
| Johnson & Johnson | 7 | $1,006 |
| Geron Corporation | 1 | $780 |
| Novartis | 18 | $305 |
| Pfizer | 15 | $291 |
| AstraZeneca | 8 | $246 |
| E.r. Squibb & Sons, L.L.C. | 8 | $240 |
| Eisai Inc. | 8 | $158 |
| GSK | 8 | $152 |
| Incyte Corporation | 3 | $121 |
| EMD Serono, Inc. | 6 | $114 |
| Gilead | 5 | $100 |
| Genmab U.S., Inc. | 4 | $85 |
| Array Biopharma Inc | 8 | $73 |
| Beigene USA, Inc. | 3 | $71 |
| Rigel Pharmaceuticals, Inc. | 2 | $55 |
| Merck | 3 | $51 |
| Ipsen Biopharmaceuticals, Inc | 1 | $50 |
| Genentech USA, Inc. | 2 | $43 |
| Bristol Myers Squibb | 2 | $42 |
| Azurity Pharmaceuticals, Inc. | 1 | $38 |
| Sanofi | 2 | $36 |
| Tersera Therapeutics LLC | 1 | $29 |
| Pharmaessentia USA Corporation | 1 | $28 |
| Tempus AI, Inc | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Novocure Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,824 in reported general payments places this provider in the 40th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 71 | $1,138,400 |
| CalquenceAcalabrutinib Maleate | 25 | $364,533 |
| IbrancePalbociclib | 21 | $194,527 |
| KisqaliRibociclib Succinate | 18 | $181,260 |
| BrukinsaZanubrutinib | 13 | $176,852 |
| TasignaNilotinib Hcl | 11 | $96,829 |
| EliquisApixaban | 19 | $13,105 |
| Abiraterone Acetate | 24 | $3,887 |
| Anastrozole | 112 | $1,774 |
| Hydroxyurea | 35 | $1,457 |
| Tamoxifen Citrate | 33 | $997 |
| Fentanyl | 12 | $752 |
| Ondansetron OdtOndansetron | 22 | $468 |
| Oxycodone Hcl | 18 | $444 |
| Prochlorperazine Maleate | 22 | $312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $246 | $364,53325 claims |
| NovartisKisqali, Tasigna | $305 | $278,09029 claims |
| PfizerIbrance, Eliquis | $291 | $207,63140 claims |
| Beigene USA, Inc.Brukinsa | $71 | $176,85213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 77 hematology & oncology providers in Utah.
Other hematology & oncology in Salt Lake City
- Neeraj AgarwalSalt Lake City$32.4M
- Douglas SborovSalt Lake City$7.8M
- Tsewang TashiSalt Lake City$6.7M
- Benjamin MaughanSalt Lake City$5.6M
- Daanish HodaSalt Lake City$2.9M
- Shiven PatelSalt Lake City$2.9M
- Vaia FlorouSalt Lake City$2.3M
- Theresa WernerSalt Lake City$1.9M
- Heloisa SoaresSalt Lake City$1.7M
- Sunil SharmaSalt Lake City$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.